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Hematopoietic stem cells (HSCs) and leukemic stem
cells (LSCs) are both capable of self-renewal, with
HSCs sustaining multiple blood lineage differentia-
tion and LSCs indefinitely propagating leukemia.
The GABP complex, consisting of DNA binding
GABPa subunit and transactivation GABPb subunit,
critically regulates HSC multipotency and self-
renewal via controlling an essential gene regulatory
module. Two GABPb isoforms, GABPb1L and
GABPb2, contribute to assembly of GABPa2b2
tetramer. We demonstrate that GABPb1L/b2 defi-
ciency specifically impairs HSC quiescence and
survival, with little impact on cell cycle or apoptosis
in differentiated blood cells. The HSC-specific effect
is mechanistically ascribed to perturbed integrity of
the GABP-controlled gene regulatory module in
HSCs. Targeting GABPb1L/b2 also impairs LSC
self-renewal in p210BCR-ABL-induced chronic mye-
logenous leukemia (CML) and exhibits synergistic
effects with tyrosine kinase inhibitor imatinib therapy
in inhibiting CML propagation. These findings iden-
tify the tetramer-forming GABPb isoforms as specific
HSC regulators and potential therapeutic targets in
treating LSC-based hematological malignancy.
INTRODUCTION
HSCs have two cardinal features, self-renewal andmultipotency,
and are responsible for sustained production of multiple blood
lineages throughout an individual’s lifetime (Orkin and Zon,
2008). The HSC counterparts in leukemias, LSCs, are also en-
dowed with unlimited self-renewal, generating the bulk leukemic
blasts (Huntly and Gilliland, 2005). The transcriptional programs
in HSCs have been greatly elucidated through transcriptomic
analysis and genome-wide mapping of binding locations of key
transcription factors (Novershtern et al., 2011; Wilson et al.,
2010). Although information on regulation of LSCs is still limited,Cexisting data indicate that both HSCs and LSCs share some
transcription factors such as Foxo3a and similar pathways
such as Pten for intrinsic control of their self-renewal capacity
(Miyamoto et al., 2007; Naka et al., 2010; Tothova et al., 2007;
Yilmaz et al., 2006; Zhang et al., 2006). Among the key transcrip-
tion factors and pathways identified to regulate HSC biological
activities, most have recurring roles in at least a subset of differ-
entiated blood cells (Novershtern et al., 2011; Orkin and Zon,
2008; Wilson et al., 2010). Such pleiotropic effects limit their
potential use as therapeutic targets.
The GA binding protein (GABP) complex, consisting of DNA-
binding GABPa subunit and transactivation GABPb subunit,
has been known to critically regulate cell cycle control, protein
synthesis, and cellular metabolism (Rosmarin et al., 2004), as
evidenced by early lethality upon germline deletion of GABPa
(Ristevski et al., 2004; Xue et al., 2004). Conditional targeting
studies also revealed that GABPa has cell-type-specific roles
in myeloid cells, as well as in T and B lymphocytes (Xue et al.,
2007; Yang et al., 2011; Yu et al., 2010). Whereas GABPa is en-
coded by a single Gabpa gene, GABPb exists in three different
isoforms: GABPb1L and GABPb1S are splice variants from the
Gabpb1 gene, and GABPb2 is produced from the Gabpb2
gene (de la Brousse et al., 1994; LaMarco et al., 1991). All GABPb
isoforms contain an N-terminal ankyrin repeat domain that
mediates interactions with GABPa (Figure 1A). However, only
GABPb1L and GABPb2 have highly homologous C-terminal
leucine-zipper domains that mediate their homodimerization or
heterodimerization (de la Brousse et al., 1994). These dimerizing
GABPb isoforms thus contribute to assembly of GABPa2b2
tetramer, when two or more consensus GABPa binding motifs
are adjacent or brought into proximity via chromatin looping
(Batchelor et al., 1998; Graves, 1998). On the other hand,
GABPb1L and GABPb1S share identical 332 amino acids in
the N termini, but GABPb1S does not contain the C-terminal
leucine-zipper structure. Thus, GABPb1S cannot form dimers
with other GABPb isoforms and does not contribute to tetramer
assembly.
It has been demonstrated that the GABP complex can inter-
face with other transcription factors or cofactors via either the
GABPa or GABPb subunit. GABPa can physically interact with
Sp1, HNF4a, and FOXA2 transcription factors or recruit the
CBP/p300 coactivator (Bush et al., 2003; Galvagni et al., 2001;ell Stem Cell 11, 207–219, August 3, 2012 ª2012 Elsevier Inc. 207
Figure 1. Analysis of GABP Motif Distribution in
HSC Genome Indicates Involvement of GABPa2b2
Tetramer
(A) Diagram showing the structure of GABPb isoforms. The
known functional domains of GABPb proteins include
ankyrin repeat domain (ANK), transactivation domain
(TAD), and leucine-zipper structure (LZ). The amino acid
boundaries of each domain are shown. Note that
GABPb1L and GABPb1S are identical from amino acids
1 to 332, and GABPb2 is highly homologous, but not
identical, to GABPb1 isoforms.
(B) Number of GABP motif occurrences within genome-
wide GABPa binding locations in HSCs. Genome-wide
GABP occupancy was mapped by ChIP-Seq, and 13,614
out of the total 15,767 GABPa binding locations in HSCs
contained at least one consensus GABP motif (Yu et al.,
2011). The pie chart shows the distribution of the number
of GABP motifs contained within the 13,614 GABPa
binding locations.
(C) Distribution of GABP motifs in GABP-bound and
GABP-activated genes. Also listed are GABP-activated
direct targets that have known critical roles in HSCs and
are measured for expression as shown in Table 1.
(D) The expression of GABP subunits/isoforms in hema-
topoietic stem/progenitor cells and differentiated blood
cells. Indicated cell populations were isolated from BM
cells or splenocytes of WT C57BL/6 mice by cell sorting.
The expression of GABPa, GABPb1L, GABPb1S, and
GABPb2 was measured by quantitative RT-PCR. The
relative expression of each transcript was normalized to
Hprt1, whose expression was arbitrarily set to 1 in each
cell population. Data are means ± SD (for Flt3 LSKs,
MPPs, and MPs, n = 9 from four experiments, and for the
rest, n = 4 from two independent experiments).
Cell Stem Cell
GABPa2b2 Tetramer in HSC and LSC Self-RenewalKang et al., 2008; Ravel-Chapuis et al., 2007; Wallerman et al.,
2009). GABPb1 can interact with non-DNA binding cofactors
including HCF, YEAF1, and YAF2 (Sawa et al., 2002; Vogel and
Kristie, 2000). All these GABPa- or GABPb-interacting factors
appear to act through the GABP complex, rather than func-
tioning in lieu of the b or a subunit, respectively. Because GABPa
is the sole DNA binding subunit, inactivation of GABPa disrupts
the activity of the entire GABP complex and abrogates its
interaction with other cooperating factors, accounting for early
embryonic lethality in Gabpa-targeted animals (Ristevski
et al., 2004; Xue et al., 2004). On the other hand, the GABPb
subunit has three coexpressed isoforms. Germline targeting of
GABPb1L or GABPb2 individually did not cause apparent abnor-
malities in embryogenesis or lymphoid lineage development
(Jing et al., 2008; Xue et al., 2008), suggesting that GABPb
isoforms have partly redundant functions and may confer fine-
tuned regulatory activities of the GABP complex.
Coupled with functional and transcriptomic analyses of
GABPa-deficient HSCs, we previously mapped genome-wide
GABPa occupancy and constructed a GABP-controlled gene
regulatory module, which includes key molecules regulating
HSC survival, quiescence, and self-renewal (Yu et al., 2011).
Due to a dominant role of GABPa in HSC survival, it was not
feasible to use GABPa-targeted animals to assess other func-
tional requirements of the GABP complex in HSCs inferred208 Cell Stem Cell 11, 207–219, August 3, 2012 ª2012 Elsevier Inc.from GABP target genes. By crossing GABPb1L- or GABPb2-
targeted strains, we have obtained double deficient (dKO)
animals in which the capacity of GABPa2b2 tetramer formation
is completely abrogated. Loss of the tetramer-forming GABPb
isoforms impaired HSC self-renewal and repopulation capacity,
specifically perturbing survival and quiescence of HSCs without
affecting more differentiated blood cells. We further demon-
strated that the tetramer-forming GABPb isoforms critically
regulated self-renewal of LSCs in a CML model and that target-
ing these proteins synergized with the tyrosine kinase inhibitor
imatinib in treating CML. These data suggest that GABPa2b2
tetramer is an HSC-specific regulator and may be explored as
a therapeutic target for eradication of LSCs.
RESULTS
Targeting GABPb1L and GABPb2 Diminished the HSC
Pool but Did Not Affect HSC Differentiation into Myeloid
or Lymphoid Progenitors
We have previously mapped genome-wide GABP occupancy in
HSCs by ChIP-Seq and found that more than 85% of GABP
binding locations contained the core consensus motif ‘‘(a/c)
GGAA(g/a)’’ (Yu et al., 2011) (Figure S1 available online). Further
motif analysis revealed that 64% of these GABP binding loca-
tions contained two or more GABP motifs (Figure 1B). In our
Figure 2. The Tetramer-Forming GABPb
Isoforms Are Required for HSC Mainte-
nance, but Not for HSC Differentiation
(A) Detection of MPs and LSKs. BM cells from
indicated mice were surface stained, and
percentages of MPs and LSKs are shown in
representative contour plots (n = 10–12 from eight
experiments).
(B) LSK frequency and numbers in whole BM cells.
The absolute counts are from two tibias and two
femurs from each mouse. Data are means ± SD
(nR 10).
(C) Detection of LT-HSCs, ST-HSCs, and MPPs.
The BM LSK cells were further fractionated based
on CD34 and Flt3 expression. The percentage of
each subset is shown.
(D) LT-HSC numbers in whole BM cells. The
absolute counts are from two tibias and two
femurs. Data are means ± SD. (n = 5–6 from four
independent experiments). *p < 0.05; **p < 0.01;
***p < 0.001.
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their transcription initiation sites (TISs) were defined as
‘‘GABP-bound genes,’’ and among these, genes that are posi-
tively regulated by GABP were defined as ‘‘GABP-activated
genes’’ (Yu et al., 2011). We found that approximately three-
fourths of both sets of genes harbored two or more GABPmotifs
(Figure 1C). It has been shown that GABPa and GABPb subunits
spontaneously form ab heterodimers, but require the presence
of at least two GABP motifs in DNA to assemble into GABPa2b2
tetramers (Chinenov et al., 2000). Therefore, ChIP-Seq with
GABPa identifies all target genes for the GABP complex, and
the number of GABP motifs in each target determines whether
an ab dimer of an a2b2 tetramer is assembled. Our motif analysis
thus suggests that regulation of most if not all of the GABP target
genes may involve assembly of GABPa2b2 tetramers. For the re-
maining one-fourth of GABP target genes that contain only one
GABP motif within 2 kb of their TISs, tetramer formation may stillCell Stem Cell 11, 207–21occur when distal GABP motifs are
brought into close proximity through
chromatin looping.
To specifically address a requirement
of GABPa2b2 tetramer-forming capacity
for regulating HSCs, we crossed germline
GABPb1L- and GABPb2-targeted mice
to obtain dKO animals in which tetramer
assembly is abrogated. Inactivation of
GABPb1L or GABPb2 alone did not
compromise normal embryogenesis or
lymphopoiesis (Jing et al., 2008; Xue
et al., 2008), and the dKO mice remained
viable, suggesting that targeting the
tetramer-forming GABPb isoforms did
not drastically disrupt the activity of
GABP complex. In contrast to massive
cell death in HSCs upon induced inactiva-
tion ofGABPa, theGABPb1L/b2-targeted
animals allowed detailed functional
characterization of the GABP complex inregulating HSCs. By quantitative RT-PCR, we confirmed that
all GABP subunits/isoforms were abundantly expressed in
bone marrow (BM) LinSca1+c-Kit+Flt3 cells (Flt3 LSKs) that
contained both long-term and short-term HSCs (LT- and ST-
HSCs; Figure 1D). Similarly, all these transcripts were detected
inmoredifferentiated progenitors including LinSca1+c-Kit+Flt3+
multipotential progenitors (MPPs), LinSca1c-Kit+ myeloid
progenitors (MPs), and mature blood lineage cells, including
BM Gr.1+ granulocytes, splenic CD3+ T cells, and B220+ B cells
(Figure 1D).
The dKO mice did not exhibit apparent defects in HSCs by
the age of 6 weeks. When observed at 8 weeks or older,
GABPb1L/ and dKO mice showed approximately 15% and
25% reductions in total BM cells, respectively (Table S1),
and exhibited more pronounced decreases in LSK frequency
and absolute counts (Figures 2A and 2B). Flt3 and CD34-based
immunophenotypic analysis of LSKs indicates that deficiency in9, August 3, 2012 ª2012 Elsevier Inc. 209
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HSCs (CD34Flt3 LSKs) to ST-HSCs (CD34+Flt3 LSKs) and
MPPs (Figure 2C), whereas LT-HSCs were decreased in abso-
lute counts in GABPb1L/ and dKO mice (Figure 2D). Similarly,
LT-HSCs defined by SLAM family receptors (CD150+CD48
LSKs) were diminished in frequency in dKO Lin BM cells
(Figure S2A). On the other hand, the frequencies of SLAM LT-
HSCs within the LSK subset were similar between dKO and
control animals, further corroborating that HSC differentiation
was not detectably affected based on SLAM markers (Fig-
ure S2B). Taken together, these observations indicate that
tetramer-forming GABPb isoforms have critical roles inmaintain-
ing a pool of HSCs and MPPs under a steady state without
affecting HSC differentiation.
In contrast to decreased LSK frequency in whole BM cells, the
frequency of MPs (Figure 2A) and LinIL-7Ra+c-KitmedSca1med
common lymphoid progenitors (CLPs, Figure S3A) was similar
among animals of all genotypes (Table S1). Further differentia-
tion of MPs in the BM, T cell development in the thymus, and B
cell development in the BM was not detectably perturbed in
either single knockout or dKO strains (Figures S3B–S3D).
Moderate decreases in cell counts of MPs and some differenti-
ated cells were observed in dKO mice (Table S1), which were
likely secondary to diminished HSC and MPP pools. These
data further support that tetramer-forming GABPb isoforms are
not required for HSC differentiation, but rather have a more
specific role in HSC maintenance.
Targeting GABPb1L and GABPb2 Impaired HSC
Self-Renewal and Repopulation Capacity
In addition to immunophenotypic analysis, we measured func-
tional HSCs by limiting dilution assays, which detected HSCs
at >10-fold lower frequency in dKO mice than in controls (Fig-
ure 3A), indicating more severely impaired HSC functionality
caused by GABPb1L/b2 deficiency. We next performed a
competitive repopulation assay by transplanting the test
(CD45.2+) and competitor (CD45.1+) BM cells at an LSK ratio
of 1:1 (Figure S4A). After R10 weeks, we found that control
and GABPb2/ BM cells contributed similarly to the way the
competitors did to peripheral blood nucleated cells (PBCs).
However, GABPb1L/ and dKO BM cells were much less
competitive, with dKO exhibiting the most diminished contribu-
tion (Figures 3B and 3C). The same trends were evident in
thymocytes, splenic T and B cells, BM B cells, and granulocytes
(Figures S4B–S4F). Importantly, GABPb1L/-derived LSKs
in recipient BM were greatly diminished, and dKO-derived
LSKs were further reduced (Figures 3D and 3E), thus account-
ing for their decreased contributions to blood lineage reconstitu-
tion. We further measured HSC self-renewal by performing
serial transplantations using sort-purified LSKs lacking
GABPb1L and/or b2. Whereas BM cells from each genotype
can reconstitute all blood lineages both short- and long-term
(8 weeks and R16 weeks, respectively), the contribution from
GABPb1L/, especially dKO LSKs, was moderately decreased
in the primary recipients (Figure 3F). In secondary recipients,
however, the multilineage contribution from GABPb1L/ and
dKO LSKs was more markedly reduced, with dKO cells consti-
tuting <10%of blood nucleated cells (Figure 3F). Together, these
results together revealed a critical requirement for tetramer-210 Cell Stem Cell 11, 207–219, August 3, 2012 ª2012 Elsevier Inc.forming GABPb isoforms in HSC self-renewal and blood lineage
reconstitution capacity.
Targeting GABPb1L and GABPb2 Specifically Affected
HSC Survival and Quiescence through Perturbation
of the GABP Gene Regulatory Module
We next investigated the underlying mechanisms accounting for
the specific regulation of HSC activity by the tetramer-forming
GABPb isoforms. Our data indicate that, compared with
GABPb2, GABPb1L exhibited a predominant role in HSC self-
renewal and repopulation capacity. HSCs lacking both factors
exhibited more severe defects than those deficient in GABPb1L
alone. This is analogous to the roles of Myc and Foxo transcrip-
tion factors in HSCs. Whereas N-Myc is dispensable for normal
hematopoiesis, c-Myc deletion specifically impaired HSC differ-
entiation without affecting HSC self-renewal (Wilson et al., 2004).
Targeting both N-Myc and c-Myc revealed an unexpected
requirement of Myc proteins in maintaining HSC survival and
proliferation (Laurenti et al., 2008). Among the Foxo transcription
factors, Foxo3a appeared to have a more predominant effect,
but triple deletion of Foxo1/3a/4 was necessary to uncover their
roles in coping with oxidative stress in HSCs (Miyamoto et al.,
2007; Tothova et al., 2007). For the GABP complex, it is thus
necessary to target both GABPb1L and GABPb2 to reveal the
complete spectrum of regulatory activity of the GABPa2b2
tetramer in HSCs. We therefore focused on dKO mice in the
following analyses.
Consistent with an absolute requirement of GABPa in HSC
survival (Yu et al., 2011), the frequencies of AnnexinV+7-AAD
apoptotic cells in the LT-HSC pool and in other LSK subsets
were increased approximately 3- to 4-fold in dKO mice (Figures
4A and 4B), demonstrating a phenocopy between GABPa and
GABPb1L/b2 deficiencies. In contrast, the frequencies of
apoptotic cells were not increased in dKO BM Gr.1+ cells or
splenic T and B cells (Figure 4C), supporting a specific role of
the tetramer-forming GABPb isoforms in survival of HSCs and
progenitor cells. Our previously defined GABP-controlled gene
regulatory module in HSCs contained 2,224 GABP-activated
direct target genes (Figure S1) (Yu et al., 2011). These included
prosurvival Bcl-2 family members (Bcl-2, Bcl-XL, and Mcl-1)
and transcription factors Zfx and Etv6, all of which are known
to critically regulate HSC survival (Galan-Caridad et al., 2007;
Hock et al., 2004b; Opferman, 2007). In sorted LT-/ST-HSCs,
we observed consistent decreases in these transcripts in dKO
mice, ranging from 15% to 34% (Table 1). In contrast, consistent
expression decreases were only observed for Bcl-2 in dKO BM
Gr.1+ cells, among all the transcripts tested in BM Gr.1+ cells
and splenic T and B cells (Table 1). These observations thus
lend molecular support to a specific role for GABPb1L/b2 iso-
forms in HSC survival.
The GABP direct targets in the gene regulatory module also
predict a role of the GABP complex in maintaining HSC quies-
cence (Yu et al., 2011). Cell cycle analysis with Hoechst 33342
and Ki-67 showed that whereas the majority of control LT-
HSCs were maintained in the Ki-67Hoechstlow G0 phase,
dKO LT-HSCs exhibited substantial reduction in the G0 dormant
state and concomitant increase in G1 and S/G2/M phases with
active cycling (Figures 4D and 4E). The dKO ST-HSCs and
MPPs showed similarly increased cycling, but this was not
Figure 3. The Tetramer-Forming GABPb Isoforms Are Essential for Repopulation Capacity and Self-Renewal of HSCs
(A) Detection of functional HSCs by limiting dilution assay. Graded numbers of test BM cells (CD45.2+) were mixed with 23 105 protector BM cells (CD45.1+) and
transplanted into irradiated congenic recipients (CD45.1+). Plotted are the percentages of recipient mice containing less than 1% CD45.2+ blood nucleated cells
at 16 weeks after transplantation. Frequency of functional HSCs was calculated according to Poisson statistics.
(B–E) Competitive repopulation assay. Test (CD45.2+) and competitor (CD45.1+) whole BM cells were mixed at a 1:1 LSK ratio and transplanted into irradiated
CD45.1+CD45.2+ recipients. After R10 weeks, their relative contributions to blood nucleated cells (B and C) and BM LSKs (D and E) were determined. The
percentages of test-, competitor-, and host-derived cells are shown in representative contour plots from three independent experiments (B and D). The
contribution of CD45.2+ test cells to PBCs and LSKs in the hosts was collectively summarized in (C) and (E), respectively.
(F) Serial transplantation assay. LSK cells were sorted from the original gene-targeted mice or primary recipients and injected into irradiated CD45.1+CD45.2+
recipients. Blood nucleated cells were analyzed at 8 and >16 weeks posttransplantation. Data are means ± SD. (n = 5–10 from two independent experiments).
*p < 0.05; **p < 0.01; ***p < 0.001.
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and 4F). By 5-bromo-20-deoxyuridine (BrdU) pulsing in vivo,
we found that all the LSK subsets (in particular LT-HSCs),
but not myeloid progenitors or mature blood cells, exhibited
a pronounced increase in proliferation in dKO mice (Figure S5).
Two GABP direct target genes, Foxo3a and Pten, are known to
restrain HSCs from hyperproliferation (Miyamoto et al., 2007;
Tothova et al., 2007; Yilmaz et al., 2006; Zhang et al., 2006). Tran-
scripts of both genes showed approximately 30% reduction in
dKO LT-/ST-HSCs and MPPs, but were not decreased in MPs
or differentiated blood cells (Table 1). The non-GABP direct
targets, cyclin-dependent kinase inhibitors p21Cip/Waf1 and
p27Kip1 (encoded by Cdkn1a and Cdkn1b, respectively), are
known to have critical roles in maintaining HSC quiescence
(Cheng et al., 2000; Walkley et al., 2005). Their expression was
not consistently altered in dKO cells (Table 1). These findingsCindicate a specific role of the tetramer-forming GABPb isoforms
in HSC cell cycle regulation and preservation of a dormant pool
of HSCs.
We also examined other GABP direct target genes that have
been reported to regulate various aspects of HSC biology,
including Atm in DNA break repair, Terf2 in telomere mainte-
nance, Dnmt1 in DNA methylation, Myst4 in histone acetylation,
and Brg1 and Brm (encoded by Smarca4 and Smarca2, respec-
tively) in chromatin remodeling.We also included Dnmt3a and 3b
DNA methyltransferases, and CBP histone acetyltransferase
(encoded by Crebbp), whose expression is dependent on
GABPa but not directly regulated by GABP at the TISs (Yu
et al., 2011). All these genes were reduced in expression in the
range of 18%–38% in dKO LT-/ST-HSCs as well as MPPs
(except for Atm in MPPs). The reductions were specific to dKO
LT-/ST-HSCs and MPPs, because consistent decreases inell Stem Cell 11, 207–219, August 3, 2012 ª2012 Elsevier Inc. 211
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Table 1. Expression of GABP Target Genes in HSCs, Progenitors, and Differentiated Blood Cells Lacking GABPb1L/GABPb2
Gene
Symbol
Flt3 LSKs (LT-HSCs
and ST-HSCs) MPPs
Myeloid
Progenitors BM Granulocytes Splenic T Cells Splenic B Cells
HSC survival Bcl2 0.66 ± 0.20*** 0.74 ± 0.17** 1.32 ± 0.31* 0.75 ± 0.18* 1.88 ± 0.71* 1.25 ± 0.95N.S.
Bcl2l1 0.85 ± 0.24* 0.65 ± 0.07*** 0.91 ± 0.37N.S. 1.13 ± 0.41N.S. 0.92 ± 0.28N.S. 1.30 ± 0.32N.S.
Mcl1 0.76 ± 0.27* 0.87 ± 0.19N.S. 0.95 ± 0.14N.S. 1.36 ± 0.29* 1.01 ± 0.21N.S. 0.88 ± 0.26N.S.
Zfx 0.72 ± 0.17** 0.92 ± 0.09N.S. 0.86 ± 0.10* 1.03 ± 0.24N.S. 1.01 ± 0.28N.S. 0.98 ± 0.20N.S.
Etv6 0.79 ± 0.24* 0.67 ± 0.38** 0.91 ± 0.15N.S. 1.23 ± 0.41N.S. 0.98 ± 0.30N.S. 0.99 ± 0.31N.S.
HSC quiescence Foxo3a 0.64 ± 0.24*** 0.61 ± 0.11** 1.06 ± 0.33N.S. 1.40 ± 0.37* 0.98 ± 0.42N.S. 1.08 ± 0.48N.S.
Pten 0.71 ± 0.20** 0.77 ± 0.18* 1.24 ± 0.30N.S. 1.10 ± 0.25N.S. 0.95 ± 0.31N.S. 0.89 ± 0.43N.S.
Cdkn1aa 0.91 ± 0.38N.S. 0.91 ± 0.11N.S. 0.77 ± 0.22* N.R.D. 0.89 ± 0.49N.S. N.R.D.
Cdkn1ba 0.78 ± 0.39N.S. 1.00 ± 0.16N.S. 0.83 ± 0.26N.S. 1.34 ± 0.45N.S. 1.33 ± 0.66N.S. N.R.D.
Other HSC
regulators
Atm 0.82 ± 0.24* 0.85 ± 0.30N.S. 1.27 ± 0.26* 1.29 ± 0.38N.S. 1.22 ± 0.14* 0.80 ± 0.37N.S.
Terf2 0.79 ± 0.17** 0.74 ± 0.13** 0.89 ± 0.07* 1.47 ± 0.73N.S. 1.25 ± 0.60N.S. 1.34 ± 0.92N.S.
Dnmt1 0.81 ± 0.25* 0.57 ± 0.15*** 0.96 ± 0.09N.S. 1.30 ± 0.34N.S. 1.30 ± 0.29N.S. 0.97 ± 0.17N.S.
Dnmt3ab 0.68 ± 0.24** 0.63 ± 0.16** 0.91 ± 0.29N.S. 1.22 ± 0.29N.S. 0.92 ± 0.05** 0.93 ± 0.09N.S.
Dnmt3bb 0.80 ± 0.26* 0.71 ± 0.13** 0.83 ± 0.16* 1.95 ± 0.60* 0.77 ± 0.25N.S. 0.65 ± 0.22*
Crebbpb 0.73 ± 0.32* 0.69 ± 0.19** 1.11 ± 0.23N.S. 1.22 ± 0.34N.S. 1.11 ± 0.27N.S. 0.86 ± 0.20N.S.
Myst4 0.70 ± 0.38* 0.71 ± 0.27* 1.04 ± 0.20N.S. 1.18 ± 0.17* 1.23 ± 0.33N.S. 0.86 ± 0.18N.S.
Smarca2 0.62 ± 0.22*** 0.63 ± 0.29** 0.94 ± 0.10N.S. 1.19 ± 0.23N.S. 1.04 ± 0.12N.S. 0.77 ± 0.18*
Smarca4 0.79 ± 0.26* 0.65 ± 0.10*** 0.90 ± 0.25N.S. 0.99 ± 0.22N.S. 1.06 ± 0.32N.S. 0.98 ± 0.20N.S.
Gabpa 1.12 ± 0.37N.S. 1.21 ± 0.40N.S. 1.28 ± 0.12** 1.82 ± 0.49** 1.90 ± 0.60N.S. 1.04 ± 0.20N.S.
Quantitative RT-PCRwas performed on each sorted population on indicated transcripts (all normalized toHprt1). Data are ratios of dKO versus control
cells expressed asmeans ± SD (n = 9 from four independent experiments for Flt3 LSKs, MPPs, andMPs; n = 4 from two independent experiments for
BM granulocytes and splenic T and B cells). N.R.D., not reliably detectable; N.S., not statistically significant; ***p < 0.001, **p < 0.01, and *p < 0.05 by
Student’s t test. Significant and consistent changes in HSCs and MPPs are highlighted in bold, and those in myeloid progenitors and differentiated
blood cells are in italics for direct comparison.
aNon-GABP target genes as unaffected controls.
bNon-GABP direct target genes affected in expression by GABPa deficiency in HSCs.
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GABPa2b2 Tetramer in HSC and LSC Self-Renewalgene expression were only occasionally observed in MPs or
other differentiated blood cells (Table 1). In contrast, GABPa
expression itself was not decreased in dKO HSCs, demon-
strating that deficiency in GABPb1L/b2 did not diminish global
gene expression in HSCs nonspecifically. In sum, the molecular
characterization revealed that loss of GABPb1L/b2 resulted in
moderate but consistent changes in the expression of multiple
targets, leading to perturbation of the overall integrity of the
GABP gene regulatory module. This evidence also corroborates
a molecular phenocopy between GABPa and GABPb1L/b2 defi-
ciencies. The regulatory effect of GABPb1L/b2 was only evidentFigure 4. Deficiency in GABPb1L/b2 Specifically Impairs HSC Survival
(A) Detection of apoptosis in HSCs and progenitors. BM cells from dKO and con
expressionwas used to define LT-HSCs, ST-HSCs, andMPPswithin the LSK subs
AnnexinV+7-AAD apoptotic cells in each subset was shown in representative c
(B) Cumulative data on frequency of apoptotic HSCs or progenitors. Data are m
(C) Apoptosis in differentiated blood cells. The frequencies of apoptotic BM gran
independent experiments). No significant differences were observed between co
(D) Cell cycle analysis of HSCs and progenitor cells. BM cells were surface-staine
percentages of Ki-67lowHoechst G0, Ki-67highHoechst G1, and Ki-67highHoec
Ki-67 positivity was based on isotype control staining.
(E) Cumulative data of cell cycle status in each LSK subset andmyeloid progenitor
N.S., not significant.
(F) Cell cycle status in differentiated blood cells. No significant differences were
Cin HSCs and not in MPs or more differentiated blood lineage
cells. One possible explanation is that the differentiated cells
may express additional regulatory factors that compensate for
the loss of GABPb1L/b2. Global mapping of histonemodification
status has revealed stark differences between the multipotent
HSCs and differentiated erythrocyte precursors (Cui et al.,
2009). It is thus possible that the histonemarks and/or chromatin
remodeling are modified in a manner specific to differentiated
cells, so that they become less sensitive to the absence of
tetramer-forming GABPb isoforms. These possibilities merit
further investigation.and Quiescence
trol mice were surface stained to identify LSKs and MPs, and CD34 and Flt3
et. These cells were further stained for AnnexinV and 7-AAD. The percentage of
ontour plots.
eans ± SD. (n = 5–6 from four experiments.)
ulocytes and splenic T and B cells are shown as means ± SD. (n = 4 from two
ntrol and dKO cells.
d as in (A) and further stained intracellularly for Ki-67 and Hoechst 33342. The
hst+ S/G2/M phase cells are shown in representative dot plots. The gating of
s. (n = 5 from three independent experiments.) *p < 0.05; **p < 0.01; ***p < 0.001;
observed between control and dKO cells.
ell Stem Cell 11, 207–219, August 3, 2012 ª2012 Elsevier Inc. 213
Figure 5. The Tetramer-Forming GABPb Isoforms Are Critical for CML Initiation and Propagation
(A) Kaplan-Meier survival curves for recipients of p210BCR-ABL-transduced Lin BM cells. Lin BM cells from mice of indicated genotypes were transduced with
a bicistronic retrovirus that expresses p210BCR-ABL along with GFP. The infected cells (each containing 6,000 GFP+ LSK cells) along with 2 3 105 protector BM
cells were transplanted into irradiated syngeneic recipients and CML progression was observed. Data in (A) and (B) are pooled results from two independent
experiments, and the p values were obtained by log-rank (Mantel-Cox) statistical analysis.
(B) Complementation of dKO BM cells with the GABPb1L gene restores sensitivity to CML induction. Lin BM cells from dKO mice were infected with
p210BCR-ABL-GFP and a pMIT retrovirus expressing GABPb1L.WT and dKO BM cells were also infected with p210BCR-ABL-GFP along with empty pMIT retrovirus
as controls. Recipients of these transduced cells were monitored for CML progression.
(C and D) Sustained generation of transformed myeloid cells depends on GABPb1L/b2. Control or dKO Lin BM cells were retrovirally transduced with
p210BCR-ABL and transplanted into irradiated syngeneic recipients as in (A). GFP+Mac1+ cells were tracked in PBCs on indicated days post-BMT. The frequency
of GFP+Mac1+ cells is marked in representative contour plots in (C) and collectively summarized in (D). Data are means ± SD from two independent experiments.
(n = 22 for control, and n = 15 for dKO).
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Regulated LSC Self-Renewal
Given their specific regulatory role in HSC self-renewal, we next
investigated if GABPb1L/b2 isoforms have a role in maintaining
LSCs. CML is a paradigmatic stem cell disorder that involves
chromosomal translocation between BCR and ABL in humans,
giving rise to the BCR-ABL fusion protein with constitutive tyro-
sine kinase activity (Wang and Dick, 2005). This disease can be
recapitulated in mice by retrovirally introducing the p210 form
of BCR-ABL (p210BCR-ABL) into cycling hematopoietic stem/
progenitor cells followed by transplantation into irradiated recip-
ients (Pear et al., 1998). We thus introduced p210BCR-ABL into
GABPb1L- and/or GABPb2-deficient Lin BM cells, and trans-
planted these cells into irradiated syngeneic recipients to induce
CML. We confirmed that delivery of p210BCR-ABL via retroviral
infection into BM cells was not negatively affected by deficiency
in GABPb1L and/or GABPb2 (Figure S6A). In addition, GABP214 Cell Stem Cell 11, 207–219, August 3, 2012 ª2012 Elsevier Inc.subunits/isoforms were neither enriched nor diminished in
expression in p210BCR-ABL-transformed LSCs (Figure S6B).
Within 20–30 days of BM transplantation (BMT), the recipients
of both control and GABPb2/ donor cells developed symp-
toms of CML-like myeloproliferative disease with increased
myeloid cells in peripheral blood (Figure 5A). Deficiency in
GABPb1L slightly prolonged recipient survival, and double defi-
ciency in GABPb1L/b2 further delayed CML initiation and
promoted recipient survival (Figure 5A). Additionally, introducing
GABPb1L into dKO Lin BM cells resensitized CML induction by
p210BCR-ABL (Figure 5B). These observations suggest that both
GABPb isoforms are important for efficiently establishing
LSCs, mirroring their roles in regulating normal HSC self-renewal
(Figure 3F).
As demonstrated above, GABPb1L/b2 are intrinsically
required for maintaining HSC homeostasis and functionality,
and thus delayed CML onset in dKO recipients might be
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ensuing generation of transformed myeloid cells. To test this,
we tracked GFP+Mac1+ cells in PBCs during early stages of
transplantation of p210BCR-ABL-infected BM cells. As shown in
Figures 5C and 5D, both WT and dKO-derived GFP+Mac1+ cells
contributed similarly to the PBCs on days 6 and 9 post-BMT.
When the recipients were examined on day 12 post-BMT, GFP+
Mac1+ cells derived from WT BM cells continued to expand, but
those fromdKOBMcells failed tomaintain the same growth rate.
In the CML model, 2 3 105 WT BM cells are transplanted
together with p210BCR-ABL-transduced cells to confer radiopro-
tection. These protector BM cells also compete for engraftment,
especially with the transduced dKOBMcells (Figures 3B–3E). To
reduce such competition and thus maximize the dKO BM
engraftment, we performed a parallel experiment in which the
same amounts of p210BCR-ABL-transduced WT and dKO BM
cells were transplanted, but the protectors for recipients of
dKO cells were reduced to 1 3 105. As shown in Figure S6C,
this approach did improve engraftment of the transduced dKO
cells, and dKO-derived GFP+Mac1+ cells persisted at similar
frequencies in PBCs as those derived from WT cells until up to
day 14 post-BMT. In spite of the similar chimerism to a much
later time point, recipients of the transduced dKO BM cells
exhibited delayed onset of CML and prolonged survival (Fig-
ure S6D). These observations indicate that the diminished sensi-
tivity to CML induction in the absence of GABPb1L/b2 cannot be
solely explained by reduced chimerism upon BM transplanta-
tion. Whereas we cannot entirely exclude the possibility that
GABPb1L/b2-deficient LSCs did not engraft as efficiently as
control LSCs in this system, the experimental evidence pre-
sented above suggests that the tetramer-forming GABPb
isoforms contribute to maintaining p210BCR-ABL-transformed
LSCs and hence sustained production of leukemic cells. In line
with this notion, we used an in vitro serial plating assay where
p210BCR-ABL-conferred self-renewing capacity was measured
by colony formation in methylcellulose media, without implica-
tions of the engraftment issue in the transplantation setting.
We have observed consistent reduction in dKO-derived colonies
after both first and second plating (Figure S6E), which lends
additional support to an intrinsic role of GABPb1L/b2 in themain-
tenance of LSCs.
To further explore the mechanism by which deficiency in
GABPb1L/b2 affects LSCs, we examined survival and cell cycle
progression of BM LSCs during days 15–20 post-BMT. We
found that dKO LSCs are more susceptible to apoptosis (Fig-
ure 6A) and that an increased fraction of dKO LSCs are in actively
cycling S/G2/M phase (Figure 6B). Thus, the reduced production
of leukemic cells and slow onset of CML in dKO recipients are
most likely ascribed to intrinsic defects in LSCs lacking the
tetramer-forming GABPb isoforms. Consistent with these obser-
vations, enumeration of LSCs (GFP+ LSK cells) in recipient
mouse BM revealed a substantial decrease in accumulation of
dKO LSCs compared with controls (Figure 6C). To directly
assess LSC self-renewal in vivo, we first induced CML in primary
recipients as described above, isolated LSCs from the BM by
cell sorting, and transplanted 10,000 LSCs into another cohort
of irradiated syngeneic mice. The control LSCs propagated
CML inR90% of the secondary recipients. In striking contrast,
only 10%of the secondary recipients of dKO LSCswere affectedCby CML (Figure 6D and Figure S6F). These findings collectively
indicate that GABPb1L/b2 proteins have essential roles in self-
renewal of LSCs as well as HSCs.
The tyrosine kinase inhibitor imatinib preferentially targets
actively dividing leukemic cells, whereas the quiescent LSCs
are resistant to imatinib and therefore account for CML relapse
in human patients (Holtz et al., 2007). We induced CML in
primary recipients as above, and initiated imatinib treatment on
day 8 post-BMT. For the recipients of p210BCR-ABL-infected
WT BM cells, the imatinib treatment prolonged their survival
compared with the untreated group, although all the treated
recipients eventually succumbed to the disease (Figure 6E).
Significantly, the imatinib treatment of recipients of p210BCR-ABL-
infected dKO BM cells further prolonged their survival, and pro-
tected R70% of them (Figure 6E). These observations suggest
that targeting self-renewing LSCs by interfering with GABPb
activity can achieve better control of leukemia in synergy with
drugs targeting bulk leukemic blasts.
DISCUSSION
Transcription factors are intrinsic determinants of HSC self-
renewal and multilineage differentiation capacity (Orkin and
Zon, 2008). Genome-wide mapping of transcription factor
binding locations and various histone marks in HSCs has greatly
advanced our understanding of the extensive crosstalk among
transcription factors and their interplay with epigenetic states
(Cui et al., 2009; Wilson et al., 2010). Many transcription factors
are known to have recurring roles in both multipotent HSCs and
differentiated blood cells in different lineages. For example, dele-
tion of PU.1, an Ets family transcription factor, greatly diminished
LSKs in fetal livers as well as adult BM and completely abrogated
generation of CMPs and CLPs from HSCs (Dakic et al., 2005;
Iwasaki et al., 2005). In addition, graded levels of PU.1 regulate
macrophage versus B cell generation, with higher concentra-
tions promoting a macrophage fate, and lower concentrations
favoring production of B cells (DeKoter and Singh, 2000). Simi-
larly, the transcriptional repressor Gfi1 is required for restraining
excessive HSC proliferation and preserving its self-renewal
capacity (Hock et al., 2004a), as well as normal T cell develop-
ment (Yu¨cel et al., 2003). Interestingly, Gfi1 was recently found
to directly repress PU.1 expression to promote B cell differenti-
ation at the expense of macrophages (Spooner et al., 2009). The
pleiotropic effect and interconnected nature of transcription
factors thus limit their potentials to be utilized as therapeutic
targets in enhancing HSC engraftments or treating hematolog-
ical malignancy. In the case of GABP complex, the GABPa
subunit has similar limitations. We have recently demonstrated
that induced deletion of GABPa subunit severely impaired HSC
survival and differentiation (Yu et al., 2011). In addition, previous
studies by our group and others revealed that GABPa is required
for B cell development by directly regulating Pax5 (Xue et al.,
2007), and for myeloid differentiation via direct regulation of
Gfi1 (Yang et al., 2011). Thus, it was quite unexpected that tar-
geting the tetramer-forming GABPb isoforms, GABPb1L and
GABPb2, would specifically affect HSC homeostasis and func-
tionality. Deficiency in GABPb1L/b2 compromised HSC survival
and quiescence, but had no detectable effect on apoptosis
or cell cycle regulation in differentiated blood cells. However,ell Stem Cell 11, 207–219, August 3, 2012 ª2012 Elsevier Inc. 215
Figure 6. Targeting GABPb1L/b2 Impairs
LSC Self-Renewal and Synergizes with ima-
tinib Therapy to Eradicate CML
(A) Intrinsic requirement of GABPb1L/b2 for LSC
survival. Fifteen to twenty days after trans-
plantation of p210BCR-ABL-infected cells, BM cells
from the primary recipients were surface stained
to identify GFP+ LSKs as LSCs. The cells were
further stained for AnnexinV and 7-AAD. The
percentage of AnnexinV+7-AAD apoptotic cells
is shown in representative contour plots and
summarized as means ± SD in the bar graph on
the right (n = 4 for control, and n = 8 for dKO).
**p < 0.01.
(B) LSCs lacking GABPb1L/b2 exhibit more active
cycling. BM cells were isolated from the primary
recipients as in (A). To avoid quenching of GFP in
LSCs, the cells were first incubated with Hoechst
33342 at 37C for 45 min, washed twice with
HBSS, and surface stained on ice. Percentages of
cells in G0/G1 or S/G2/M phases are shown in
representative histograms and are summarized in
the bar graph on the right (n = 4 for Ctrl, and n = 8
for dKO). **p < 0.01.
(C) Enumeration of LSCs in primary recipients.
Primary recipients of p210BCR-ABL-transduced BM
cells were sacrificed on day 15 post-BMT, and
GFP+ LSK cells in the BM were determined.
Representative data from three independent
experiments are shown. ***p < 0.001.
(D) CML propagation in secondary recipients.
GFP+ LSK cells were sorted from primary recipi-
ents of p210BCR-ABL-transduced BM cells on day
15 post-BMT. Ten thousand sorted cells were in-
jected into another cohort of syngeneicmice along
with 23 105 protectors, and CML progressionwas
monitored.
(E) Synergistic effect of GABPb1L/b2 deficiency
and imatinib therapy in controlling CML in vivo.
Primary recipients of p210BCR-ABL-transduced BM
cells were untreated or treated with imatinib
(100 mg/kg body weight, b.i.d.) from day 8 to day
80 post-BMT, with CML progression monitored.
Data in (D) and (E) are pooled results from two
independent experiments, and statistical signifi-
cance was assessed using log-rank test.
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GABPa2b2 Tetramer in HSC and LSC Self-RenewalLT-HSCs lacking GABPb1L/b2, albeit reduced in absolute
counts, were capable of differentiation to ST-HSCs and MPPs
within the LSK population and generation of CMPs and CLPs
at the frequency similar to that of control LT-HSCs. These find-
ings suggest that the activity of the GABP complex can be
modulated via its GABPb isoforms to dissociate HSC survival/
self-renewal from HSC differentiation.
Such a specific role for the tetramer-forming GABPb isoforms
in HSCs is substantiated at the gene expression level. The216 Cell Stem Cell 11, 207–219, August 3, 2012 ª2012 Elsevier Inc.GABPb1L/b2 dKO mouse model allowed
us to determine how target genes for the
GABP complex in HSCs are regulated
through these tetramer-forming GABPb
isoforms. Out of the GABP-controlled
gene regulatory module in HSCs, we
sampled dozens of GABP direct or indi-rect target genes that have known critical roles in regulating
different aspects of HSC biology. Whereas acute deletion of
GABPa in HSCs led to >10-fold reduction in some target genes
for the GABP complex, including Bcl-2, Zfx, Pten, Atm, and Brm
(Yu et al., 2011), targeting GABPb1L/b2 isoforms resulted in
more subtle decreases in all these genes in LT-/ST-HSCs and
MPPs. Such moderate gene expression reductions in dKO
HSCs/MPPs were consistent and widespread in almost all
GABP targets examined. This may also help explain our inability
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GABPa2b2 Tetramer in HSC and LSC Self-Renewalto identify HSC biology-relevant, validatable targets for
GABPb1L/b2 via microarray-based transcriptomic analysis of
dKO and control HSCs (data not shown). Although the qPCR-
mediated gene expression profiling of dKO HSCs is not neces-
sarily exhaustive, our data suggest that the tetramer-forming
GABPb isoforms confer a fine-tuned digital regulation of target
genes for the GABP complex. Rather than causing drastic
changes in one or a few particular target genes, deficiency in
GABPb1L/b2 perturbs the integrity of the GABP-controlled
gene regulatory module. The combinatorial effects of small
changes on multiple gene targets thus lead to functional impair-
ments of HSC survival, quiescence, self-renewal, and
repopulation capacity. Significantly, the impact on gene expres-
sion is highly specific for HSCs and MPPs. Consistent gene
expression reductions were rarely seen in myeloid progenitors
or granulocytes in the BM, or in splenic T or B cells lacking
GABPb1L/b2, thus offering a molecular explanation for the
specific regulation of HSC activity by these GABPb isoforms.
The role of GABPb1S in the GABP complex has been contro-
versial. When fused with a GAL4 DNA-binding domain, both
GABPb1L and GABPb1S were found to be equally proficient in
activating transcription (Gugneja et al., 1995); however, others
reported that GABPb1S failed to activate transcription using
in vitro reporter assays (Sawa et al., 1996). Additionally, a C-ter-
minal truncated form of GABPb1 encompassing amino acids
1–330, which is common to both GABPb1L and GABPb1S, has
been shown to have a dominant-negative effect against the
GABP complex (Briguet and Ruegg, 2000; Schaeffer et al.,
1998). In GABPb1L/b2 dKO mice, GABPb1S is the only remain-
ing GABPb isoform and forms GABPa/GABPb1S heterodimer
with GABPa2b2 tetramer assembly abrogated. If GABPb1S were
to have a dominant effect, the GABPb1L/b2 dKO mice would be
expected to have similar phenotypes as in GABPa-targeted
animals, such as early embryonic lethality. The fact that dKO
mice remain viable indicates that the GABP a2b2 tetramer
assembly is dispensable for embryogenesis and that the
GABPa/GABPb1S heterodimer has essential regulatory roles in
transcription activation/repression rather than functioning as
a dominant-negative. However, the GABPa/GABPb1S hetero-
dimer was not sufficient to optimally activate transcription of crit-
ical GABP target genes in the context of HSCs, because the loss
of GABPb1L/b2 impaired HSC survival and quiescence.
Previous biochemical and structural studies have established
that the GABPa2b2 tetramer binds to target DNA sequences
with increased affinity and stability compared with ab dimers
(Batchelor et al., 1998; Chinenov et al., 2000; Graves, 1998).
Our motif analysis of genome-wide GABP binding locations
revealed that approximately three-fourths of GABP target genes
harbor two or more GABP binding motifs in their proximal regu-
latory sequences. Whereas heterodimers between GABPa and
individual GABPb isoforms may maintain the ability to activate
GABP targets, the presence of two or more motifs within
one GABP binding location should facilitate the assembly of
GABPa2b2 tetramer, which activates GABP target genes to an
optimal level that meets functional requirements in HSCs.
Although our data cannot actively exclude the possibility that
GABPb1L and b2 have tetramer-independent functions, it is
more likely that GABPa2b2 tetramer forms naturally in vivo wher-
ever two ormoreGABPmotifs are present in or recruited to prox-Cimal gene regulatory sequences. Overall, the optimal expression
of GABP-controlled gene regulatory module in HSCs requires
assembly of GABPa2b2 tetramer. GABPb2
/ HSCs did not
exhibit detectable defects, indicating that loss of a2(b2)2 tetra-
mers is compensated for by the a2(b1L)2 tetramers. On the other
hand, GABPb1L/ HSCs retained the ability of assembling
a2(b2)2 tetramers yet exhibited impaired repopulation capacity
and self-renewal. A possible explanation could be that a2(b1L)2
tetramers have a more potent regulatory role than a2(b2)2 tetra-
mers, analogous to c-Myc among the Myc proteins and Foxo3a
among the Foxo transcription factors (Laurenti et al., 2008;
Tothova et al., 2007).
Of particular interest is that the essential roles of tetramer-
forming GABPb isoforms in HSC self-renewal are extended to
LSCs. Understanding molecular wiring in LSCs is of importance
given the promise of eradicating leukemia by targeting LSCs.
Although molecular characterization of LSCs is currently less
extensive compared with that of HSCs, existing evidence indi-
cates that LSCs from different hematological malignancies share
common transcriptional regulators for their self-renewal. For
example, a requirement of b-catenin has been demonstrated in
both CML and acute myelogenous leukemias (Wang et al.,
2010; Zhao et al., 2007). Additionally, LSCs and HSCs share
some common regulators for their self-renewal, including two
GABP direct targets, Pten and Foxo3a (Miyamoto et al., 2007;
Naka et al., 2010; Tothova et al., 2007; Yilmaz et al., 2006;
Yu et al., 2010; Zhang et al., 2006). Our data demonstrate that
targeting GABPb1L/b2 impairs LSC initiation and propagation
in a CML model, indicating that both HSCs and LSCs depend
on the tetramer-forming GABPb isoforms for self-renewal. It
is of note that targeting GABPb1L/b2 more strongly impaired
LSC initiation in primary recipients compared with targeting
other factors, such as promyelocytic leukemia protein or
Foxo3a, where suppression of LSC self-renewal became evident
only in secondary or tertiary recipients (Ito et al., 2008; Naka
et al., 2010). We further showed that the combination of
GABPb1L/b2 deficiency and imatinib therapy synergistically
controlled CML initiation. These observations provide a key
rationale for exploring the tetramer-forming GABPb isoforms
as therapeutic targets to eliminate LSCs without severely
compromising the function of differentiated blood cells, particu-
larly the immune cells. Because these GABPb isoforms are also
required for normal HSCs and hence hematopoiesis, upon
completion of the LSC-targeted chemotherapy, allogeneic
HSC transplantation would be necessary to restore a sustained
supply of blood cells.EXPERIMENTAL PROCEDURES
Mice
GABPb1L/ and GABPb2/ mice were described previously (Jing et al.,
2008; Xue et al., 2008). All mouse experiments were performed under proto-
cols approved by the Institutional Animal Use and Care Committee of the
University of Iowa.
BM Reconstitution Assays
For limiting dilution assay, graded numbers of test (dKO or control) BM
cells (7 3 103, 2.2 3 104, 6.7 3 104, and 2 3 105) were mixed with 2 3 105
protector B6.SJL BM cells and transplanted into lethally irradiated B6.SJL
recipients. Sixteen weeks later, contribution of test cells to multilineage bloodell Stem Cell 11, 207–219, August 3, 2012 ª2012 Elsevier Inc. 217
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GABPa2b2 Tetramer in HSC and LSC Self-Renewalreconstitution was determined by flow cytometry. For serial transplantation
assay, 1,500–2,500 sorted LSKs were transplanted into lethally irradiated
CD45.1+CD45.2+ mice, and 8 weeks later, a portion of the primary recipient
mice was sacrificed, and CD45.2+ LSKs were sorted again and transplanted
into secondary recipients at 1,500 cells/mouse.
CML Model and imatinib Therapy
p210BCR-ABL retrovirus was packaged and used to infect Lin BM cells. The
infected cells containing 6,000 GFP+ LSK cells along with 2 3 105 protector
BM cells were transplanted into lethally irradiated C57BL/6 recipients to
induce CML (Chen et al., 2009; Ito et al., 2010). The recipients were then eval-
uated daily for lethargy, splenomegaly, and signs of morbidity. For imatinib
treatment, the drug was administered at 100 mg/kg body weight by oral
gavage twice a day, during 8–80 days after transplantation of p210BCR-ABL-
infected Lin BM cells.
SUPPLEMENTAL INFORMATION
Supplemental information for this article includes six supplemental figures,
one supplemental table, and Supplemental Experimental Procedures and
can be found with this article online at http://dx.doi.org/10.1016/j.stem.2012.
05.021.
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